Are the following areas under pre-clinical development, plus the GBM delivery system under re-design, what you are considering is the IP we are developing (in collab or otherwise)... that will underpin future patent applications by CHM?
- Undisclosed Next-Gen CAR NK study in blood and/or solid tumours (CHM 3301)
- CAR NK-cell study with CDH17 in solid tumours (CHM 2301)
- CAR NK-cell with CLTX (CHM 1301)
- CAR T-cell with CLTX in solid tumours (CHM 1101)
- CAR T-cell with CDH17 in solid tumours (CHM 2101)
If so, then some data readouts from any one of the above studies in the lab/s would be welcome. Pre-clinical data always seems to excite the masses, Bec!!! There is a lot of potential asset value there for CHM to trot out!
CHM Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)